89 assets in Prostate Adenocarcinoma

Therapeutic assets addressing Prostate Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Docetaxel Prostate Adenocarcinoma	Instituto do Cancer do Estado de São Paulo	P3	BBB (72)
Cyclophosphamide Prostate Adenocarcinoma	Beijing Biotech	P2	BB (70)
Degarelix Prostate Adenocarcinoma	Canadian Cancer Trials Group	P3	BB (70)
Nilutamide Prostate Adenocarcinoma	SWOG Cancer Research Network	P3	BB (70)
Prednisone Prostate Adenocarcinoma	Mayo Clinic	P3	BB (70)
Bicalutamide Prostate Adenocarcinoma	OHSU Knight Cancer Institute	P3	BB (69)
Goserelin Prostate Adenocarcinoma	CancerCare Manitoba	P3	BB (69)
Leuporelin Prostate Adenocarcinoma	Mayo Clinic	P3	BB (69)
Cediranib Prostate Adenocarcinoma	National Cancer Institute (NCI)	P2	BB (68)
Flutamide Prostate Adenocarcinoma	NRG Oncology	P3	BB (68)
Histrelin Prostate Adenocarcinoma	NRG Oncology	P3	BB (68)
Piflufolastat Prostate Adenocarcinoma	Sean Sachdev	P4	BB (67)
Vipivotide Tetraxetan Prostate Adenocarcinoma	Mayo Clinic	P3	BB (67)
Cabazitaxel Prostate Adenocarcinoma	ECOG-ACRIN Cancer Research Group	P3	BB (66)
Darolutamide Prostate Adenocarcinoma	Region Stockholm	P3	BB (66)
Indocyanine Green Prostate Adenocarcinoma	Ankara University	P4	BB (65)
Cabozantinib Prostate Adenocarcinoma	University of Utah	P3	BB (64)
Abiraterone Prostate Adenocarcinoma	Mayo Clinic	P3	B (63)
Enzalutamide Prostate Adenocarcinoma	Prostate Cancer Clinical Trials Consortium	P3	B (63)
Relugolix Prostate Adenocarcinoma	National Cancer Institute, Naples	P3	B (63)
Apalutamide Prostate Adenocarcinoma	Alliance for Clinical Trials in Oncology	P3	B (62)
Atorvastatin Prostate Adenocarcinoma	Tampere University Hospital	P3	B (62)
Carboplatin Prostate Adenocarcinoma	University of Washington	P2	B (62)
Dinitrogen Monoxide Prostate Adenocarcinoma	Beth Israel Deaconess Medical Center	P4	B (62)
Ipilimumab Prostate Adenocarcinoma	M.D. Anderson Cancer Center	P2	B (61)
Pembrolizumab Prostate Adenocarcinoma	OHSU Knight Cancer Institute	P2	B (61)
Niraparib Prostate Adenocarcinoma	Mayo Clinic	P2	B (60)
Nivolumab Prostate Adenocarcinoma	Emory University	P2	B (60)
Oxygen Prostate Adenocarcinoma	Beth Israel Deaconess Medical Center	P4	B (60)
AXUMIN Prostate Adenocarcinoma	NRG Oncology	P3	B (59)
Flotufolastat F 18 Prostate Adenocarcinoma	Icahn School of Medicine at Mount Sinai	P2	B (59)
Talazoparib Prostate Adenocarcinoma	Prostate Cancer Clinical Trials Consortium	P2	B (59)
Dexasone Prostate Adenocarcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (58)
Itraconazole Prostate Adenocarcinoma	University of Chicago	P2	B (58)
Rucaparib Prostate Adenocarcinoma	Alliance for Clinical Trials in Oncology	P3	B (58)
Vorinostat Prostate Adenocarcinoma	Fred Hutchinson Cancer Center	P2	B (58)
25-HYDROXYCALCIFEROL Prostate Adenocarcinoma	University of Ilorin Teaching Hospital	P3	B (57)
Atezolizumab Prostate Adenocarcinoma	University of Utah	P3	B (57)
Copper Cu 64 Psma I Prostate Adenocarcinoma	Curium US LLC	P3	B (57)
Testosterone Cipionate Prostate Adenocarcinoma	University of Washington	P2	B (57)
Olaparib Prostate Adenocarcinoma	Rana McKay, MD	P2	CCC (55)
Buserelin Prostate Adenocarcinoma	NRG Oncology	P3	CCC (54)
Fludarabine Prostate Adenocarcinoma	Beijing Biotech	P1/2	CCC (54)
Aglatimagene Besadenovec Prostate Adenocarcinoma	Candel Therapeutics, Inc.	P2	CCC (53)
AVOLVE Prostate Adenocarcinoma	Toni Choueiri, MD	P2	CCC (53)
Bet Bromodomain Inhibitor Zen-3694 Prostate Adenocarcinoma	Rahul Aggarwal	P2	CCC (53)
Etoposide Prostate Adenocarcinoma	University of Washington	P2	CCC (53)
Fezolinetant Prostate Adenocarcinoma	Shehzad Basaria, M.D.	P2	CCC (53)
Fk-Pc101 Prostate Adenocarcinoma	Cellvax Therapeutics Inc	P2	CCC (53)
Fludeoxyglucose Prostate Adenocarcinoma	Fred Hutchinson Cancer Center	P2	CCC (53)

Showing 1 to 50 of 89 assets

PreviousPage 1 of 2Next